Literature DB >> 11426976

The clinical significance of occult macroscopically positive retroperitoneal nodes in patients with epithelial ovarian cancer.

S M Eisenkop1, N M Spirtos.   

Abstract

OBJECTIVE: The goal of this study was to determine the time during primary cytoreduction when retroperitoneal lymph nodes that are involved with macroscopic disease are recognized to be involved with tumor, the dimensions of intranodal disease present, and the possible clinical significance of macroscopically positive nodes that are recognized at different phases of the operation.
METHODS: One hundred consecutive patients with stage IIIC and IV epithelial ovarian cancer underwent a retroperitoneal lymph node dissection during primary cytoreductive surgery. The phase of the operation in which nodes were recognized to be macroscopically involved with tumor was noted. Nodes were classified to be positive by palpation if recognized to be macroscopically involved by transperitoneal palpation, positive by inspection if recognized to be macroscopically involved by palpation after opening the retroperitoneal area, and positive by dissection if recognized to be macroscopically involved anytime after starting the actual process of lymph node dissection. The largest dimension of the intranodal disease in macroscopically positive nodes was measured. Log rank analysis determined whether nodal status or the time at which the nodes were recognized to be macroscopically positive influenced the probability of survival.
RESULTS: Of the 100 patients, 66 had positive lymph nodes. Five were microscopically positive and 61 were macroscopically positive, of which 19 (31.1%) were positive by palpation, 16 (26.2%) were positive by inspection, 26 (42.6%) were positive by dissection. Of the 39 patients with negative and microscopically positive nodes 15 (38.5%) were clinically suspicious. Compared with patients with negative and microscopically positive lymph nodes, survival was not significantly different for patients who required excision of macroscopically positive nodal tissue. Survival was not influenced by the specific phase of surgery in which macroscopically positive nodes were recognized.
CONCLUSIONS: A significant percentage of patients had retroperitoneal nodes recognized to be involved with macroscopic disease only after a lymph node dissection was in progress. The decision not to perform a lymph node dissection for optimally and completely cytoreduced patients may result in unrecognized macroscopic residual disease that is larger than what would otherwise be documented. Copyright 2001 Academic Press.

Entities:  

Mesh:

Year:  2001        PMID: 11426976     DOI: 10.1006/gyno.2001.6232

Source DB:  PubMed          Journal:  Gynecol Oncol        ISSN: 0090-8258            Impact factor:   5.482


  13 in total

Review 1.  Lymphadenectomy in Ovarian Cancer: Is It Still Justified?

Authors:  Pierluigi Benedetti Panici; Andrea Giannini; Margherita Fischetti; Francesca Lecce; Violante Di Donato
Journal:  Curr Oncol Rep       Date:  2020-02-08       Impact factor: 5.075

2.  Ovarian cancer development and metastasis.

Authors:  Ernst Lengyel
Journal:  Am J Pathol       Date:  2010-07-22       Impact factor: 4.307

3.  What is the role of retroperitoneal exploration in optimally debulked stage IIIC epithelial ovarian cancer? An NRG Oncology/Gynecologic Oncology Group ancillary data study.

Authors:  Bunja J Rungruang; Austin Miller; Thomas C Krivak; Neil S Horowitz; Noah Rodriguez; Chad A Hamilton; Floor J Backes; Linda F Carson; Michael Friedlander; David G Mutch; Michael J Goodheart; Krishnansu S Tewari; Robert M Wenham; Michael A Bookman; G Larry Maxwell; Scott D Richard
Journal:  Cancer       Date:  2016-11-16       Impact factor: 6.860

4.  Primary Ovarian Carcinoma with Rectal Metastasis-a Rare Presentation (a Case Report).

Authors:  Deepjyoti Kalita; Srinivas Bannoth; Abhijit Talukdar; Joydeep Purkayastha; Pritesh Singh; Jitin Yadav; Niju Pegu
Journal:  Indian J Surg Oncol       Date:  2019-06-05

5.  Role of systematic lymphadenectomy as part of primary debulking surgery for optimally cytoreduced advanced ovarian cancer: Reappraisal in the era of radical surgery.

Authors:  Kyung Jin Eoh; Jung-Yun Lee; Jung Won Yoon; Eun Ji Nam; Sunghoon Kim; Sang-Wun Kim; Young Tae Kim
Journal:  Oncotarget       Date:  2017-06-06

6.  Nerve growth factor modulates the tumor cells migration in ovarian cancer through the WNT/β-catenin pathway.

Authors:  Bo Li; Shaoxi Cai; Yi Zhao; Qiyi He; Xiaodong Yu; Longcong Cheng; Yingfeng Zhang; Xiancheng Hu; Ming Ke; Sijia Chen; Misha Zou
Journal:  Oncotarget       Date:  2016-12-06

7.  Role of Lymphadenectomy During Interval Debulking Surgery Performed After Neoadjuvant Chemotherapy in Patients With Advanced Ovarian Cancer.

Authors:  Minjun He; Yuerong Lai; Hongyu Peng; Chongjie Tong
Journal:  Front Oncol       Date:  2021-03-26       Impact factor: 6.244

8.  Diagnosis and management of peritoneal metastases from ovarian cancer.

Authors:  Evgenia Halkia; John Spiliotis; Paul Sugarbaker
Journal:  Gastroenterol Res Pract       Date:  2012-07-19       Impact factor: 2.260

9.  Role of primary surgery in advanced ovarian cancer.

Authors:  Karsten Münstedt; Folker E Franke
Journal:  World J Surg Oncol       Date:  2004-10-02       Impact factor: 2.754

10.  The potential therapeutic role of lymph node resection in epithelial ovarian cancer: a study of 13918 patients.

Authors:  J K Chan; R Urban; J M Hu; J Y Shin; A Husain; N N Teng; J S Berek; K Osann; D S Kapp
Journal:  Br J Cancer       Date:  2007-05-22       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.